Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

QDEL vs UFPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UFPT Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

UFPT Overall Winner 6-Pillar Tally: QDEL 2 – 4 UFPT Matrix Metrics: QDEL 3 – 7 UFPT

As of Nov 16, 2026, UFP Technologies Inc (UFPT) is the stronger overall head-to-head candidate over QuidelOrtho Corporation (QDEL) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). QDEL carries a Unified Composite Score of 43.9/100 (HOLD) at $10.21 (7.8x Forward P/E, 0.2% operating margin), whereas UFPT carries 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin).

  • Composite vs. Pillar Nuance: While QDEL currently prints a higher short-term Unified Composite Score (43.9/100 HOLD vs. UFPT 42.6/100 HOLD), UFPT captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (15.4% vs. 0.2% operating margin) and revenue trajectory (+11.6% vs. -11.6% YoY).
  • Technical & Structure Timing Caution: QDEL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.6); meanwhile UFPT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About QDEL vs UFPT
QDEL NASDAQ
QuidelOrtho Corporation Common Stock
In Vitro & In Vivo Diagnostic Substances
$10.21
-4.93% 1D
Market Cap $736.9M
TTM Revenue $2.59B
Forward P/E 7.8x
Beta / 30D Vol 2.72β · 108% Vol
Unified Composite Score
43.9 / 100 HOLD
Tech 50.0 Fund 49.0 Flow 57.0 Mom 36.2
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.7%), weak momentum, RSI 39
RSI-14: 38.6 · SMA20: $12.87 · SMA50: $12.24
UFPT NASDAQ Head-to-Head Winner
UFP Technologies Inc
Surgical & Medical Instruments & Apparatus
$298.54
-2.14% 1D
Market Cap $2.4B
TTM Revenue $650M
Forward P/E 24.7x
Beta / 30D Vol 1.64β · 77% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 37.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.1%) with fading momentum, RSI 50
RSI-14: 49.8 · SMA20: $298.97 · SMA50: $293.17

6-Pillar Scorecard Institutional Category Breakdown (QDEL 2 – 4 UFPT)

Columns: Metric · QDEL · UFPT
1. Valuation Multiples QDEL
Forward P/E 7.8x 24.7x
Trailing P/E 9.6x 31.2x
PEG Ratio 2.06x 3.80x
EV / Revenue 1.4x 3.6x
2. Growth & Scale UFPT
Revenue Growth (YoY) -11.6% +11.6%
Earnings Growth (YoY) -77.1% +25.1%
TTM Revenue (USD) $2.59B $650M
Market Cap $736.9M $2.4B
3. Profitability & Quality UFPT
Gross Margin 44.5% 28.9%
Operating Margin 0.2% 15.4%
Net Profit Margin -14.2% 11.8%
Return on Equity (ROE) -19.3% 17.2%
4. Balance Sheet & Cash Flow UFPT
Cash Generation (TTM) -$118M $120M EBITDA
Cash Flow Margin -4.5% 18.5% EBITDA Mgn
Net Cash / Leverage $2.95B Net Debt (1.74x D/E) $62.70 Book/Sh · 17.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning UFPT
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 101.3% (23rd %ile) 42.3% (3rd %ile)
Put/Call OI Skew 3.30x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Distribution
6. R&D & Supply-Chain Moat QDEL
OpEx & R&D Intensity 44.3% of Rev ($1.15B) 13.5% of Rev ($88M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: QDEL (3) vs UFPT (7)
Institutional Metric QDEL UFPT Criterion Row Edge
Market Capitalization
Scale
$736.9M $2.4B Larger Scale UFPT
Trailing P/E Ratio
Valuation
9.6x 31.2x Lower Multiple QDEL
Forward P/E Ratio
Valuation
7.8x 24.7x Lower Multiple QDEL
Revenue Growth (YoY)
Growth
-11.6% +11.6% Higher Growth UFPT
Operating Margin (TTM)
Profitability
0.2% 15.4% Higher Margin UFPT
Net Profit Margin
Profitability
-14.2% 11.8% Higher Margin UFPT
Return on Equity (ROE)
Capital Efficiency
-19.3% 17.2% Higher ROE UFPT
52-Week Range Position
Momentum
1% ($10–$36) 74% ($174–$342) Stronger Trend UFPT
Beta / 30D Volatility
Risk Regime
2.72β · 108% Vol 1.64β · 77% Vol Lower Realized Risk UFPT
Unified Institutional Score
Composite Signal
43.9 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite QDEL
Trailing 12M Revenue (USD)
Operating Scale
$2.59B $650M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.5% 28.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.06x PEG · 1.4x EV/Rev 3.80x PEG · 3.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$118M ($2.95B Net Debt (1.74x D/E)) $120M EBITDA ($62.70 Book/Sh · 17.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon UFPT +23.27 pp
QDEL: -20.91% · UFPT: +2.36%
3M Horizon UFPT +19.06 pp
QDEL: -23.98% · UFPT: -4.92%
6M Horizon UFPT +43.25 pp
QDEL: -5.81% · UFPT: +37.44%
1Y Horizon UFPT +81.39 pp
QDEL: -53.97% · UFPT: +27.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QDEL vs UFPT. Trailing 12-month operating profitability (QDEL 0.2% vs UFPT 15.4%) and valuation multiples (QDEL 7.8x vs UFPT 24.7x Forward P/E) are benchmarked directly in Pillar 4 below.

QDEL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.59B
Gross Margin44.5%
Op. Margin0.2%
ROE / Fwd P/E-19.3% · 7.8x
UFPT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$650M
Gross Margin28.9%
Op. Margin15.4%
ROE / Fwd P/E17.2% · 24.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
QDEL BREAKDOWN
90d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 23rd %ile
Put/Call OI Skew 3.30x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact QDEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
UFPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 42.3%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UFPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
QDEL Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $736.9M market capitalization and 0.2% operating margin.
OpEx & R&D Reinvestment 44.3% of Rev ($1.15B)
90D Engineering Disclosures 0 Published
UFPT Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $2.4B market capitalization and 15.4% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($88M)
90D Engineering Disclosures 0 Published

Investor FAQ QDEL vs UFPT Key Questions & Quantitative Answers

As of Nov 16, 2026, UFP Technologies Inc (UFPT) is the stronger overall head-to-head candidate over QuidelOrtho Corporation (QDEL) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). QDEL carries a Unified Composite Score of 43.9/100 (HOLD) at $10.21 (7.8x Forward P/E, 0.2% operating margin), whereas UFPT carries 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin). Composite vs. Pillar Nuance: While QDEL currently prints a higher short-term Unified Composite Score (43.9/100 HOLD vs. UFPT 42.6/100 HOLD), UFPT captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (15.4% vs. 0.2% operating margin) and revenue trajectory (+11.6% vs. -11.6% YoY). Technical & Structure Timing Caution: QDEL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.6); meanwhile UFPT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

UFPT leads the Growth & Scale pillar: QDEL posts -11.6% YoY revenue growth and -77.1% YoY earnings growth on $2.59B TTM revenue (44.5% gross margin, 0.2% operating margin), compared with UFPT at +11.6% YoY revenue growth and +25.1% YoY earnings growth on $650M TTM revenue (28.9% gross margin, 15.4% operating margin). On trailing 12-month operating scale, QDEL generates $2.59B in USD-normalized revenue versus $650M for UFPT. In operating R&D and SG&A reinvestment, QDEL deploys 44.3% of Rev ($1.15B) (0 90-day corporate R&D disclosures) versus 13.5% of Rev ($88M) (0 disclosures) for UFPT.

QDEL screens cheaper on headline valuation multiples. QDEL trades at 7.8x Forward P/E, 9.6x Trailing P/E, 2.06x PEG, and 1.4x EV/Revenue (-4.5% FCF margin), whereas UFPT trades at 24.7x Forward P/E, 31.2x Trailing P/E, 3.80x PEG, and 3.6x EV/Revenue (18.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against QDEL (-19.3% ROE) versus UFPT (17.2% ROE) capital efficiency.

In options market volatility and institutional positioning, QDEL carries 101.3% implied volatility (23rd %ile, Compressed (<25th %ile)), a 3.30x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.72β · 108% Vol realized risk). By comparison, UFPT carries 42.3% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 77% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.